Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma.
Saved in:
| Title: | Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma. |
|---|---|
| Authors: | Scalambra, Laura1 (AUTHOR), Ruzzi, Francesca1 (AUTHOR) francesca.ruzzi2@unibo.it, Pittino, Olga Maria1 (AUTHOR), Semprini, Maria Sofia1 (AUTHOR), Cappello, Chiara1 (AUTHOR), Angelicola, Stefania1,2 (AUTHOR), Palladini, Arianna3,4 (AUTHOR), Nanni, Patrizia1 (AUTHOR), Goksøyr, Louise5 (AUTHOR), Fougeroux, Cyrielle5 (AUTHOR), Penichet, Manuel L.6 (AUTHOR), Sander, Adam Frederik5,7 (AUTHOR), Lollini, Pier-Luigi1,2 (AUTHOR) pierluigi.lollini@unibo.it |
| Source: | Journal of Translational Medicine. 1/30/2025, Vol. 23 Issue 1, p1-15. 15p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 14795876 |
|---|---|
| DOI: | 10.1186/s12967-025-06126-w |
